FDA Approves First-in-Class Blood Pressure Pill That May Also Shield Kidneys
AstraZeneca's Baxfendy just became the first aldosterone synthase inhibitor cleared by the FDA, winning approval in May 2026 for blood pressure that stays stubbornly high on other drugs. Trial data show big systolic drops — and an early hint that it might protect damaged kidneys too.
- Original source: scitechdaily.com.
- The source published it on Nov 19, 2026 at 8:23 AM.
- No second outlet has reported it yet. Treat it as a single-source claim.
The FDA approved AstraZeneca's Baxfendy, known generically as baxdrostat, in May 2026 for adults whose hypertension stays inadequately controlled on existing treatments. It is the first aldosterone synthase inhibitor ever cleared — a new drug class that cuts production of the hormone aldosterone instead of blocking its receptors the way older medicines do. Aldosterone governs sodium and water balance, and when levels run high the kidneys hold onto fluid, pushing blood pressure up and potentially driving kidney inflammation and scarring.
The Phase 3 BaxHTN trial put the drug through its paces in 796 patients. After 12 weeks, the 2 mg dose knocked systolic blood pressure down by an average of 15.7 mm Hg, versus 5.8 mm Hg for placebo — an extra 9.8 mm Hg reduction that was statistically significant. The lower 1 mg dose also delivered meaningful improvements. "We have been waiting for an innovative medication like Baxfendy for hypertension for many years," said Dr. Bryan Williams, chair of medicine at University College London and the trial's primary investigator, who called the placebo-adjusted drop "exciting and clinically meaningful" and noted that a 10 mmHg decrease in systolic pressure tracks with roughly 20% lower risk of serious cardiovascular events.
A second Phase 3 study, Bax24, tested 218 patients and found baxdrostat lowered average systolic blood pressure across a full 24 hours by 14.0 mm Hg more than placebo, an effect that held steady day and night, according to findings published in The Lancet. That round-the-clock coverage matters for patients whose pressure refuses to budge on multiple drugs.
The kidney signal comes from the Phase 2 FigHTN trial, which randomly assigned 192 patients with chronic kidney disease and uncontrolled hypertension to baxdrostat or placebo on top of standard treatment. After 26 weeks, systolic blood pressure fell an average of 8.1 mm Hg more in the baxdrostat groups, and urinary albumin — a protein that flags kidney damage — came in 55% lower than placebo, per results published in the Journal of the American Society of Nephrology. "The reduction in urine albumin gives us hope that baxdrostat may also help delay kidney damage," said lead study author Jamie P. Dwyer, M.D., a professor of medicine at University of Utah Health, adding that two large Phase 3 trials are now testing whether the drug actually slows kidney disease progression.
Safety has a caveat. In that earlier kidney trial, elevated blood potassium showed up in 41% of baxdrostat recipients versus 5% on placebo — mostly mild or moderate, though excess potassium can trigger dangerous heart rhythm problems — and serious adverse events hit 9% of baxdrostat patients against 3%. Later Phase 3 hypertension studies turned up no unexpected safety findings, but potassium levels and kidney function still need monitoring during treatment.
For now the FDA approval covers hypertension only, not preventing kidney disease from worsening. Researchers are running larger trials to see whether baxdrostat preserves kidney function over time, including combinations with dapagliflozin, an established kidney-protective drug. "This medication class could be a game changer in the management of hypertension in this patient group," said Jordana B. Cohen, M.D., M.S.C.E., immediate past chair of the American Heart Association's Hypertension and Kidney Cardiovascular Science Committee, who highlighted that chronic kidney disease patients — long excluded from drug studies — were represented in their own trial and tolerated the medication well.
TopicsAstraZeneca · Baxfendy · baxdrostat · FDA · Bryan Williams · Jamie P. Dwyer · Jordana B. Cohen · dapagliflozin
Source: scitechdaily.com
Written by AI from verified reporting.
More stories
- Health & science finance.yahoo.com 2 sources 0 viewsFDA clears Regeneron's RNAi myasthenia drug at $410,000 a year
- Health & science apnews.com 0 viewsA spacecraft's call takes 24 hours to cross 16 billion miles to Earth
- Health & science theguardian.com 1 viewNew Report Reveals Over 500 Moves To Roll Back Cancer Protections
- Health & science finance.yahoo.com 3 sources 1 viewHumacyte Files FDA Application to Add Dialysis Access as Second ATEV Use

